Local News

• Monsanto Company completes acquisitions of CanaVialis and Alellyx  Monsanto announced that it has completed its proposed acquisition of Aly Participacoes, which operates the sugarcane breeding and technology companies, CanaVialis and Alellyx, both of which are based in Brazil.
  Monsanto Company December 02, 2008  
• Monsanto to leverage its technology to enhance yield and economic value for farmers  As farmers in the U.S. are making their initial seed purchase decisions for the 2009 growing season, Monsanto Company plans to discuss the reasons behind its confidence that it can make good on its commitment to more than double its fiscal 2007 gross profit by 2012.
  Monsanto Company December 02, 2008  
• GSK and Theravance announce positive phase 2b results for LABA, `444  GlaxoSmithKline and Theravance announced positive results from the phase 2b study of the novel, long-acting beta agonist (LABA) GW642444 (‘444) in patients with moderate to severe asthma.
  GlaxoSmithKline December 02, 2008  
• ETHICON completes divestiture of Professional Wound Care Business to One Equity Partners  ETHICON, a Johnson & Johnson company, announced that it has completed the divestiture of its Professional Wound Care business to One Equity Partners. Financial terms of the transaction are not being disclosed.
  Johnson & Johnson December 01, 2008  
• Johnson & Johnson announces definitive agreement to acquire Mentor  Johnson & Johnson and Mentor Corporation, a leading supplier of medical products for the global aesthetic market, announced a definitive agreement whereby Mentor will be acquired for approximately $1.07 billion in a cash tender offer.
  Johnson & Johnson December 01, 2008  
• Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain  Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain.
  Eli Lilly and Company November 28, 2008  
• MedImmune receives FDA Complete Response letter on motavizumab  AstraZeneca announced that MedImmune, its wholly owned biologics business, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) asking for additional information on motavizumab.
  AstraZeneca November 28, 2008  
• Wyeth and Progenics announce positive outcome of Phase 3 study of subcutaneous RELISTOR  Wyeth Pharmaceuticals and Progenics Pharmaceuticals announced that a phase 3 clinical study investigating RELISTOR(R) subcutaneous injection to treat opioid-induced constipation (OIC) in patients with chronic, non-cancer pain achieved statistical significance for the primary endpoints.
  Progenics Pharmaceuticals, Inc. November 26, 2008  
• FDA issues Complete Response letter for ceftobiprole  Johnson & Johnson Pharmaceutical Research & Development, announced that it received a Complete Response letter from the FDA regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.
  Johnson & Johnson November 26, 2008  
• Pfizer’s novel HIV/AIDS treatment SELZENTRY fully approved  The U.S. Food and Drug Administration has granted SELZENTRY(TM) full approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. SELZENTRY was originally granted accelerated conditional approval in August 2007.
  Pfizer Inc. November 26, 2008  

   (next 10 articles)